Antibiotic Resistance and Pathogenicity of Bacterial Infections Research Group
Research group of the Health Research Institute of the Balearic Islands (IdiSBa, Group information). Founded in 2002 and accredited as a competitive research group by the Autonomous Community of the Balearic Islands, the group is composed of basic and clinical researchers from the Son Espases University Hospital (HUSE, Service information) from various specialties, with extensive experience and a long-standing collaborative trajectory in the field of infectious disease research.
The group is part of the Consorcio Centro de Investigación Biomédica en Red (CIBER) in Infectious Diseases (CIBERINFEC) of the Carlos III Health Institute (ISCIII).
Latest news
In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.
Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R Abstract: The antimicrobial resistance is a significant public health threat, particularly for healthcare-associated infections caused by carbapenem-resistant Gram-negative pathogens which are increasingly reported worldwide. The aim of this...
Neonatal SARS-CoV-2 immunoglobulin G antibodies at delivery and their impact on COVID-19.
Vetter-Laracy S; Jimenez V; Roldán M; Bernardino M; Balliu-Badia P; Lara P; Arcay RM; Fraile-Ribot P; Vila M; Fanjul F Abstract: To assess neonatal SARS-CoV-2 anti-spike IgG antibody levels after maternal mRNA COVID-19 vaccination and/or infection during pregnancy and evaluate their protective effect. Prospective observational study, conducted from January 2021 to December 2022. Infants were tested for anti-spike IgG antibodies...
Considerations to the comments on the recommendations of the Spanish Antibiogram Committee (COESANT) for the preparation of Cumulative Antibiotic Sensitivity Reports.
Navarro F; Oliver A; Larrosa MN Abstract: Enfermedades infecciosas y microbiologia clinica (English ed.): 2024 doi: 10.1016/j.eimce.2024.05.006 https://pubmed.ncbi.nlm.nih.gov/38763864
An unexpected cause of myopericarditis in an immunocompromised patient.
González de Herrero E; Moreno V; Martín-Pena ML; Ruiz de Gopegui E Abstract: Enfermedades infecciosas y microbiologia clinica (English ed.): 2024 doi: 10.1016/j.eimce.2024.04.003 https://pubmed.ncbi.nlm.nih.gov/38697869
Comparative analysis of acute respiratory infections of viral etiology in children under 6 months with and without nirsevimab in the Balearic Islands (2022-2023 and 2023-2024).
Reina J; Iturbe A; Viana-Ramírez J; Sbert G; Carrasco J; Dueñas J Abstract: Since 2023, a monoclonal antibody (nirsevimab) specifically directed against the preF form of RSV has been marketed in Spain. The impact of late immunization in the population
[Impact in the adult population of immunization with nirsevimab in children under 6 months of age against respiratory syncytial virus].
Reina J; Viana-Ramirez J Abstract: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia: 2024 doi: 10.37201/req/049.2024 https://pubmed.ncbi.nlm.nih.gov/39010814